Flash Report 3 minutesRegister for Free AccessCVS Health (CVS) 4Q15 Results: Strong Growth Aided by Acquisitions Coresight Research February 10, 2016 Executive Summary CVS Health reported that 4Q15 net sales rose by 11.0% year over year, to $41.1 billion, slightly above the consensus estimate of $41.0 billion. Diluted non-GAAP EPS rose by 26.5% year over year, to $1.53, which was in line with the consensus estimate and within the guidance range of $1.51–$1.55. Pharmacy sales grew by 11.1%, to $26.5 billion, driven by growth in specialty drugs and the recent $10 billion acquisition of pharmaceutical distributor Omnicare. The company reaffirmed its FY16 forecast of non-GAAP EPS of $5.73–$5.88, in line with consensus of $5.82. For 1Q, CVS expects non-GAAP EPS of $1.14–$1.17, slightly below the consensus estimate of $1.18. Please Login to read the full report. Not a member? To access this content for free, register for a free account. This document was generated for Other research you may be interested in: Kohl’s CEO Removal—Why It Happened and What It Means for US Department StoresWeekly US and UK Store Openings and Closures Tracker 2025, Week 8: US Store Closures Exceed 3,000, Up 420% Year Over YearRetailTech: Three Technologies Landlords Can Use to Take Malls to the Next LevelUS Retail in the Rest of 2025: Normalized Demand and Leaner Inventories Ahead of a High-Stakes Holiday Season